Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

m/discount

on short-term investments (29) (177)

Change in valuation of warrants (89) -

Other 1 36

Changes in operating assets and

liabilities:

Other assets (163) (420)

Accounts payable and

accrued liabilities (315) (1,178)

Deferred rent 181 466

Net cash used in operating activities (8,699) (10,091)

Investing activities:

Purchases of property and equipment (187) (3,990)

Purchases of short-term investments (468) (6,263)

Maturities of short-term investments 500 14,900

Restricted cash (120) -

Net cash provided by (used in)

investing activities (275) 4,647

Financing activities:

Proceeds from debt - 4,362

Payments on debt (1,476) (1,186)

Issuance of common stock and warrants 177 10,207

Net cash provided by (used in)

financing activities (1,299) 13,383

Net increase (decrease) in cash

and cash equivalents (10,273) 7,939

Cash and cash equivalents at

beginning of period 26,362 14,249

Cash and cash equivalents at

end of period $ 16,089 $ 22,188

Supplemental non-cash activities:

Capitalized interest recorded as

property, plant and equipment $ 63 $
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...if., Nov. 6 Intarcia Therapeutics,...A 650 (DUROS® continuous delivery of exenatid... the Ninth Annual Diabetes Technology Meeting in S....com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, C...TCA 650 Lowers Plasma Glucose, HbA1c and Reduces W...
(Date:11/5/2009)...Colo., Nov. 5 The endangered black...estern U.S. This rare carnivore feeds on prairie ...lague and often entire population die-offs in town...S) has implemented a ferret breeding program and h...eir formerly native habitat. Unfortunately, plagu...
(Date:11/5/2009)...all on Thursday, November 5, 2009 at 4:30 p.m. Eas.../PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals...XI ) today reported unaudited financial results fo...r 30, 2009 and reviewed the Company,s highlights f...consolidated results reflect the operations of Onc...
(Date:11/5/2009)...Texas, Nov. 5 Wound Mana... that it has entered into a Letter of Intent to pu...alth Technologies, Inc. (OTC Bulletin Board: VHGI)... in cash and debt, 4,000,000 shares of WNDM and a ...n the Veriscrip technology being acquired from VHG...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
... Michael Bruns brings extensive...panding Chicago-based clinical software company; w...ization as well as manage the company,s financial...L (PRWEB) March 19, 2009 -- ClearTrial ( www.clear...software for clinical trial operations planning, b...
...NG, Mich., March 19 Neogen Corporation (Nasdaq: ...ed by the declining global economy, its third quar...d third quarter for the 26-year-old company, compa... nine-month revenues rose 17% in the current fisca... , , Year-to-date net income for the first nin...
...ntments Strengthen Expertise in Immunotherapy of C... (Nasdaq: MITI ), a biopharmaceutical company de...atment of cancer, inflammation and autoimmune dise...alter Bodmer and Bernard Fox to its BiTE antibody ...isory panel include professors Richard Flavell ( Y...
Other Biology Technology:ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer 2ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer 3Neogen Reports Record Third Quarter 2Neogen Reports Record Third Quarter 3Neogen Reports Record Third Quarter 4Neogen Reports Record Third Quarter 5Neogen Reports Record Third Quarter 6Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 2Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 3Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 4Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 5
(Date:11/6/2009)...open for the Society of Interventional Radiology,s...ies" Webinar, which will provide the latest update...iver tumors, kidney tumor ablation and lung tumor ...ians, scientists and allied health professionals d...ring advances in image-guided therapy. , The Web...
(Date:11/6/2009)... -- Auburn Hills, MI-based Law Enforcement Intelli...cker system and patent-pending Biometric Access Co...Health and Human Services, National Institutes of ...stem will support the NIH,s entire police force th...cal research agency. The project is expected to b...
(Date:11/5/2009)...ale University have developed synthetic molecules ... HIV and HIV-infected cells, as well as to prostat...n the Journal of the American Chemical Society , ...se diseases. , The molecules called "antibody-...tibody-recruiting molecule targeting prostate canc...
Breaking Biology News(10 mins):Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Millin Associates has the Perfect Solution for Hospitals 26 Health Centers Dealing With an Influx of Uninsured Patients 53540 1Millin Associates has the Perfect Solution for Hospitals 26 Health Centers Dealing With an Influx of Uninsured Patients 53540 2One in 10 High School Seniors Have Used Narcotic Painkillers 53538 1One in 10 High School Seniors Have Used Narcotic Painkillers 53538 2One in 10 High School Seniors Have Used Narcotic Painkillers 53538 3Boston Scientific to Participate in BMO Capital Markets Health Care Conference 53533 1
...ion among chimpanzees has found that the tradition...opulations—western, central and eastern—is underpi...ree times greater than the variation between the m...007 issue of the journal PLOS Genetics, researcher...ad Institute and Arizona State show that there has...
...s multiple sclerosis (MS) has been noted in recent...ause of this increase. One theory, similar to the ...free environment may contribute to an increase in ...ases may play a role in increasing autoimmune dise...ionship between parasite infections and MS in huma...
...ammatory disorder of the intestinal tract that aff... world. Common symptoms include abdominal pain and...th debilitating clinical complications. Researcher...uncovered an important clue to the susceptibility ... association study with more than 300,000 single n...
Other Biology News:Gene study shows three distinct groups of chimpanzees 2Parasite infection may benefit MS patients 2
Endotoxin Free Water from Mo Bio Laboratories, Inc.
Chicken Anti-GBL Polyclonal Antibody, Unconjugated from ProSci, Inc
DEPC water from Mo Bio Laboratories, Inc.
Chicken Anti-TLN2 Polyclonal Antibody, Unconjugated from ProSci, Inc
Biology Products: